arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Bio Essence Corp

BIOE
Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
72
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

Bio Essence Corp demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap
Dividend Yield
Revenue Growth 2155.8%
Op. Margin 43.1%
ROIC -15.0%
FCF / Share $-0.01
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.04
info Valuation on last close.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$500.54K
↑ +2155.8%
Net Income Profit after all expenses
$205.37K
↓ -80.0%
Operating Margin Operating profit as % of sales
43.1%
↓ -38.1% 96th
FCF / Share Free cash flow per share
$-0.01
↓ -1236.2%
Long-Term Debt Long-term obligations
$57.16K
↓ -0.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
98
Returns
18
Financial Health
99
Cash Quality
83

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters